Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
Related Questions
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?
What approach, or dosing interval, do you find is most effective reducing side effects of Hedgehog Inhibitors (i.e., vismodegib) for patients with numerous BCC?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
What is your preferred treatment for actinic cheilitis?
What’s your approach to treating multiple facial BCCs in gorlin syndrome?
